Kingdon Capital Management, L.L.C. Nuvation Bio Inc. Transaction History

Kingdon Capital Management, L.L.C.

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Aug 15, 2022	SELL	$3.24 - $5.85 $1.37 Million - $2.48 Million	-423,500 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$7.75 - $10.05 $3.28 Million - $4.26 Million	423,500 New	423,500 $3.6 Million

152

123M

9.7K

6.5K

Ticker NUVB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 217,244,000
Market Cap $480M
Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...

Get notified when there are updates to the investment portfolio of Kingdon Capital Management, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Kingdon Capital Management, L.L.C. with notifications on news.